TY - JOUR T1 - Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated to the total number of main oncogenic anomalies in cancer patients JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1319 LP - 1319 VL - 61 IS - supplement 1 AU - Amin Haghighat Jahromi AU - Geraldine Chang AU - Razelle Kurzrock AU - Carl Hoh Y1 - 2020/05/01 UR - http://jnm.snmjournals.org/content/61/supplement_1/1319.abstract N2 - 1319Background: Cancer diagnosis and therapy is quickly moving from the traditional histology-based approaches to genomic stratification, providing a huge opportunity for radiogenomics: associating imaging features with genomic data. Genome sequencing is time consuming, expensive and invasive whereas (18F-fluorodeoxyglucose positron emission tomography/computed tomography) 18F-FDG PET/CT is readily available, fast and non-invasive. The aim of this study is to determine the relationship between the maximum standardized uptake value (SUVmax) and the frequency of 11 common oncogenic anomalies determined by specific common genomic alterations in tissue biopsies from patients with cancer. Method: We retrospectively studied 102 consecutive untreated patients with gastrointestinal, lung and breast cancer who underwent 18F-FDG PET/CT imaging, shortly prior to molecular testing by a biopsy for genomic profiling that consisted of 11 common DNA alterations: (1) TP53, (2) DNA repair, (3) EGFR, (4) PI3K/AKT/MTOR (PAM) pathway including PTEN, PIK3CA, AKT, TSC, CCNB1, MTOR, FBXW2, and NF2, (5) MEK, (6) CYCLIN including CCND,CDK, CDKN, and RB, (7) WNT, (8) ALK, (9) MYC, (10) MET, and (11) FGF/FGFR. Results: Higher SUVmax value was associated with the presence of TP53 and PAM genomic anomalies (p < 0.05), but not the other 9 gene groups (p > 0.05). More importantly, SUVmax value was positively correlated with total number of oncogenic anomalies (r = 0.27, p = 0.005). Conclusion: We propose higher SUVmax as an indicator for total number of common oncogenic anomalies. This finding is a step forward in non-invasive stratification of cancer patients, in terms of the overall load of oncogenic anomalies, based on their SUVmax. ER -